| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |